Arbutus Biopharma (ABUS)
Develops chronic HBV therapies while monetizing legacy lipid-nanoparticle IP.
$5.03
vs last close+0.03 (+0.67%)
Something off on this page? Send us feedback.
Next report
Nov 16, 26
in 55 days
EPS estimate
−$0.02
Revenue estimate
$1.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.07−$0.13$0.01−$0.04−$0.01$0.87−$0.03Pending
Estimate−$0.08−$0.09−$0.02−$0.06−$0.04−$0.03−$0.02−$0.02
Surprise+12.5%−44.4%+150.0%+28.6%+71.5%+3,000.0%−50.0%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.6M$1.8M$10.7M$529.0K$1.1M$179.1M$1.0MPending
Estimate$2.3M$2.2M$1.6M$841.0K$614.5K$750.0K$700.0K$1.0M
Surprise−30.3%−21.3%+575.0%−37.1%+71.0%+23,783.5%+44.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.02 | — | — |
| Sep 2027 | −$0.02 | — | — |
| Jun 2027 | −$0.02 | — | — |
| Mar 2027 | −$0.02 | — | — |
| Dec 2026 | −$0.02 | — | — |
| Nov 2026 | −$0.02 | — | — |
| Aug 2026 | −$0.02 | −$0.03 | −50.0% |
| May 2026 | −$0.03 | $0.87 | +3,000.0% |
| Mar 2026 | −$0.04 | −$0.01 | +71.5% |
| Nov 2025 | −$0.06 | −$0.04 | +28.6% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.02 | — | — | $1.0M | — | — | — |
| Sep 2027 | −$0.02 | — | — | $1.0M | — | — | — |
| Jun 2027 | −$0.02 | — | — | $1.0M | — | — | — |
| Mar 2027 | −$0.02 | — | — | $1.0M | — | — | — |
| Dec 2026 | −$0.02 | — | — | $1.0M | — | — | — |
| Nov 16, 2026 | −$0.02 | — | — | $1.0M | — | — | — |
| Aug 12, 2026 | −$0.02 | −$0.03 | −50.0% | $700.0K | $1.0M | +44.9% | −1.7% |
| May 13, 2026 | −$0.03 | $0.87 | +3,000.0% | $750.0K | $179.1M | +23,783.5% | 0.0% |
| Mar 23, 2026 | −$0.04 | −$0.01 | +71.5% | $614.5K | $1.1M | +71.0% | +4.3% |
| Nov 13, 2025 | −$0.06 | −$0.04 | +28.6% | $841.0K | $529.0K | −37.1% | −5.8% |
| Aug 6, 2025 | |||||||
| May 14, 2025 | |||||||
| Mar 27, 2025 | |||||||
| Nov 6, 2024 | |||||||
| Aug 1, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 7, 2023 | |||||||
| Aug 3, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Mar 3, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 5, 2021 | |||||||
| Mar 4, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 7, 2020 | |||||||
| May 11, 2020 | |||||||
| Mar 5, 2020 | |||||||
| Nov 6, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 6, 2019 | |||||||
| Mar 7, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 2, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 14, 2018 | |||||||
| Nov 2, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 4, 2017 | |||||||
| Mar 21, 2017 | |||||||
| Nov 3, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 4, 2016 | |||||||
| Mar 9, 2016 | |||||||
| Nov 5, 2015 | |||||||
| Aug 5, 2015 |